Tumoral C-reactive protein and nuclear factor kappa-B expression are associated with clinical outcome in patients with prostate cancer

2012 ◽  
Vol 10 (2) ◽  
pp. 91-99 ◽  
Author(s):  
Pamela McCall ◽  
Jamie Catlow ◽  
Peter A McArdle ◽  
Donald C McMillan ◽  
Joanne Edwards
Keyword(s):  
Prostate Cancer ◽  
Clinical Outcome ◽  
Nuclear Factor Kappa B ◽  
Nuclear Factor ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Nuclear Factor Kappa

scholarly journals Persistent Activation of Nuclear Factor Kappa-B Signaling Pathway in Patients With Unstable Angina and Elevated Levels of C-Reactive Protein

2007 ◽  
Vol 49 (2) ◽  
pp. 185-194 ◽  
Author(s):  
Giovanna Liuzzo ◽  
Matteo Santamaria ◽  
Luigi M. Biasucci ◽  
Michela Narducci ◽  
Valeria Colafrancesco ◽  
...  
Keyword(s):  
Unstable Angina ◽  
Signaling Pathway ◽  
Nuclear Factor Kappa B ◽  
Nuclear Factor ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Nuclear Factor Kappa

Nuclear factor-kappa B p65 evaluation on the Canadian Prostate Cancer Biomarker Network (CPCBN) TMA-series for biomarker validation.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 80-80
Author(s):  
Fred Saad ◽  
Veronique Ouellet ◽  
Andree-Anne Grosset ◽  
Christine Caron ◽  
Veronique Barres ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastasis ◽  
Nuclear Factor Kappa B ◽  
Large Cohort ◽  
Nuclear Factor ◽  
Biochemical Relapse ◽  
Nuclear Factor Kappa ◽  
Positive Nucleus ◽  
Biomarker Validation ◽  
Increased Risk

80 Background: The CPCBN has assembled a TMA-based resource comprising the specimens of 1512 prostate cancer patients treated by radical prostatectomy. This richly annotated and multi-institutional resource is available to researchers who wish to access a large cohort to validate prognostic biomarkers (http://www.tfri.ca/en/research/translational-research/cpcbn.aspx). Over the last decade, our laboratory demonstrated with an independent cohort (Gannon PO, et al. Eur J Cancer. 2013 Jul;49(10):2441-8, Labouba I, et al. PLoS One. 2015 Jul 17;10(7):e0131024), the reproducible association of nuclear factor-kappa B (NF-kB) p65 with patient’s risk of biochemical recurrence. Here, we evaluated the CPCBN TMA-series for p65 expression. Methods: Two independent observers scored the frequency of p65 nuclear localisation on digital images obtained after automated immunohistochemistry analysis of p65. Over the available minimum 3 cores of tumour tissue per patient, an average percentage of positive nucleus frequency was used. Statistical analyses were performed using SPSS software. Results: High nuclear frequency of NF-kB p65 (cut-off at 3%) was associated with an increased risk for patients to experience a biochemical relapse (p < 0.001; Exp(B) = 1.599; 95%CI = 1.321-1.937), develop bone metastasis (p = 0.007; Exp(B) = 2.126; 95%CI = 1.234-3.663)and die from their disease (p = 0.001; Exp(B) = 3.117; 95%CI = 1.55-6.266). In multivariate analyses, p65 also remained independent from clinical parameters (PSA, Gleason score and pTNM): biochemical relapse (p = 0.005; Exp(B) = 1.331; 95%CI = 1.092-1.623), bone metastasis (p = 0.033; Exp(B) = 1.82; 95%CI = 1.04- 3.158), mortality (p = 0.007; Exp(B) = 2.626; 95%CI = 1.298-5.312) Conclusions: Using a large cohort of Canadian men, our study reiterates the previous study linking NF-kB p65 with prostate cancer progression and highlights the suitability of CPCBN TMAs for biomarker validation. Our results also reveal the role of p65 as a predictor of bone metastasis development and prostate cancer-specific mortality.

Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer

2013 ◽  
Vol 49 (10) ◽  
pp. 2441-2448 ◽  
Author(s):  
Philippe O. Gannon ◽  
Laurent Lessard ◽  
Louis-Mathieu Stevens ◽  
Valérie Forest ◽  
Louis R. Bégin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Large Scale ◽  
Nuclear Factor Kappa B ◽  
Prognostic Biomarker ◽  
Nuclear Factor ◽  
Independent Validation ◽  
Nuclear Factor Kappa
Sign in / Sign up

Export Citation Format

Share Document